Background and Purpose-Although intracellular zinc accumulation has been shown to contribute to neuronal death after cerebral ischemia, the mechanism by which zinc keeps on accumulating to cause severe brain damage remains unclear. Herein the dynamic cause-effect relationships between zinc accumulation and reactive oxygen species (ROS) production during cerebral ischemia/reperfusion are investigated. Methods-Rats were treated with zinc chelator, ROS scavenger, mitochondria-targeted ROS inhibitor, or NADPH oxidase inhibitor during a 90-minute middle cerebral artery occlusion. Cytosolic labile zinc, ROS level, cerebral infarct volume, and neurological functions were assessed after ischemia/reperfusion. Results-Zinc and ROS were colocalized in neurons, leading to neuronal apoptotic death. Chelating zinc reduced ROS production at 6 and 24 hours after reperfusion, whereas eliminating ROS reduced zinc accumulation only at 24 hours. Furthermore, suppression of mitochondrial ROS production reduced the total ROS level and brain damage at 6 hours after reperfusion but did not change zinc accumulation, indicating that ROS is produced mainly from mitochondria during early reperfusion and the initial zinc release is upstream of ROS generation after ischemia. Suppression of NADPH oxidase decreased ROS generation, zinc accumulation, and brain damage only at 24 hours after reperfusion, indicating that the majority of ROS is produced by NADPH oxidase at later reperfusion time. Conclusions-This study provides the direct evidence that there exists a positive feedback loop between zinc accumulation and NADPH oxidase-induced ROS production, which greatly amplifies the damaging effects of both. These findings reveal that different ROS-generating source contributes to ischemia-generated ROS at different time, underscoring the critical importance of spatial and temporal factors in the interaction between ROS and zinc accumulation, and the consequent brain injury, after cerebral ischemia/reperfusion. Visual Overview-An online visual overview is available for this article.
) homeostasis plays an important role in normal brain functions. Normally, zinc is tightly regulated in the brain; disturbance of zinc homeostasis, however, has been found to be involved in neurological diseases. 1 Previously, studies showed that toxic influx of zinc may be a key mechanism underlying selective neuronal death after transient global ischemic insults. 2, 3 We reported recently that focal cerebral ischemia induced abnormally high concentration of Zn 2+ accumulation in the neurons, resulting in neuronal apoptosis. 4 Treatment with zinc chelator N,N,N′,N′-tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) even at 30 minutes after reperfusion reduced the accumulation of intracellular zinc, leading to a significant reduction in infarction volume, improved functional outcomes, as well as dramatic improvement in the survival rate, indicating that high level of zinc accumulation is an important causal factor for neuronal death after stroke. 4 However, the reason why zinc keeps on accumulating after cerebral ischemia/reperfusion and produces severe brain damage remains to be elucidated.
Extensive evidence indicates that cerebral ischemia results in an elevated oxidative stress because of generation of reactive oxygen species (ROS), including superoxide anions, hydrogen peroxide, and hydroxyl radicals. ROS generation has been reported to come from various sources.
The traditional view of pathology-associated ROS is that they are produced by mitochondria, cyclooxygenase, monoamine oxygenase, and xanthine oxidase, and these sources have indeed been linked to many neurological diseases. Recent studies suggest that NADPH oxidase is a major source of neuronal ROS production in hypoglycemia and other conditions. 5, 6 Although ROS formation has been demonstrated to be of particular pathophysiological significance in ischemic stroke, 7 the sources, mechanisms, and time course of ROS generation during ischemia/reperfusion are not clearly understood.
ROS and intracellular zinc are intimately related. On the one hand, ROS production can lead to oxidation of proteins, such as MT III (metallothionein III) that normally binds the metal. Although zinc itself is redox-inactive, MT III is readily oxidized because of the low redox potential of its thiols (−366 mV), thereby releasing zinc in cytoplasmic compartments. On the other hand, not only can zinc impair mitochondrial function, leading to excessive ROS production, but it can also activate a variety of extra-mitochondrial ROS-generating signaling cascades. 1, 8 Zinc could act on mitochondria to increase superoxide production 9 and induce neuronal NADPH oxidase activation in neuronal cultures. 10 Various neuroprotective measures against zinc toxicity attenuate zinc-induced increases in ROS in parallel. Zinc chelation prevents the translocation of p47 phox and p67 phox subunits of NADPH oxidase from the cytoplasm to the plasma membrane after glucose deprivation. 5 Our recent study showed that excess zinc promoted ROS production under hypoxic conditions, leading to cell death.
11
However, the temporal order and the cause-effect relationships between zinc accumulation and ROS production in ischemic brain remain unclear.
To investigate the interaction between zinc and ROS in the ischemic brain and to explore the dynamic relationships of cytosolic labile zinc accumulation in relation to various ROSgenerating systems during cerebral ischemia/reperfusion, a rat model of focal cerebral ischemia/reperfusion was used in this study. Zinc accumulation and ROS production in the penumbra tissue were measured. We also investigated whether chelating zinc would decrease ROS level in the ischemic tissue and whether decreasing ROS level by ROS scavenger, mitochondria-targeted ROS inhibitor, or NADPH oxidase inhibitor would reduce intracellular zinc level in the ischemic tissue and the subsequent brain damage.
Methods
This article adheres to the American Heart Association Journals implementation of the Transparency and Openness Promotion Guidelines. The data that support the findings of this study are available from the corresponding author on reasonable request.
Rat Model of Focal Cerebral Ischemia/Reperfusion
Animal protocols were approved by the Institutional Animal Care and Use Committee of Xuanwu Hospital of Capital Medical University and in accordance with the principles outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male Sprague-Dawley rats (280-300 g) were anesthetized with 3.5% enflurane in N 2 O:O 2 (70%:30%). Focal cerebral ischemia was induced using the modified intraluminal filament method. Female rats were not used because the current study was designed to provide the proof of concept for the interaction of zinc with ROS. The animals underwent 90 minutes of right middle cerebral artery occlusion (MCAO) and then were reperfused for 6 or 24 hours by withdrawal of the filament, as we previously described. 4 Success of MCAO model was assessed by observing animal circling to the nonischemic side at the end of ischemia and further confirmed by 2,3,5-triphenyltetrazolium chloride staining at the end of reperfusion.
Drug Administration and Experimental Groups
TPEN (Sigma-Aldrich, St Louis, MO) was dissolved in 10% dimethylsulfoxide to a final concentration of 5 mmol/L. TPEN at a dose of 15 mg/kg IP, selected based on our previous study, 4 was administered to the rats 30 minutes before MCAO. Eukarion-134 (EUK-134; Sigma-Aldrich), a synthetic ROS scavenger having both manganese-dependent superoxide dismutase and catalase activity, was dissolved in 0.1% dimethylsulfoxide. EUK-134 at 10 mg/kg, SC, total of 3 doses were administered: 30 minutes before MCAO and 3 and 8 hours after reperfusion. 12 Mitochondria-targeted ROS inhibitor R(+) pramipexole [R(+)PPX] (Sigma-Aldrich), a synthetic aminobenzothiazol derivative that blocks permeability transition pores, restores the integrity of mitochondrial membranes, and limits ROS production, was dissolved in saline. R(+)PPX at 1 mg/kg, IP, total of 5 doses were administered: 8 hours and 30 minutes before MCAO, immediately after reperfusion; 8 and 16 hours after reperfusion.
, 12, 13 The NADPH oxidase inhibitor diphenyliodonium (DPI; Sigma-Aldrich) at 0.2 mg/kg was IP administered intraperitoneally 30 minutes before MCAO. 14 Rats were assigned randomly to 6 groups using a random number table: vehicle-treated sham-operated group, vehicle-treated MCAO group, TPEN-treated MCAO group, EUK-134-treated MCAO group, R(+)PPX-treated MCAO group, and DPI-treated MCAO group. Each group was further divided into 2 subgroups according to different reperfusion time (6 and 24 hours; n=8 in each subgroup). A sample size of 8 animals per subgroup was a priori calculated based on previous research from our group. 4, 15 Six rats with unsuccessful MCAO were excluded from this study. No rats died because of surgical or stroke complications.
Measurement of Neurological Deficits
At 6 and 24 hours after reperfusion, neurological deficits were assessed blindly with 3 methods: Zea-Longa score, 4 Ludmila Belayev, 16 and forelimb foot-fault-placing test.
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Tissue Collection, Determination of Infarct Volume, and Penumbra Identification
Rats were decapitated at the end of 6 or 24 hours reperfusion, brains harvested and sectioned into three 2-mm-thick coronal slices from a 6-mm-thick region 5 mm away from the tip of the frontal lobe. The first and third slices were incubated in 1% 2,3,5-triphenyltetrazolium chloride (Sigma-Aldrich) solution at 37°C for 20 minutes to measure the infarct volume as previously described 4 by investigators blinded to the experimental groups. The remaining brain tissues were snap-frozen in liquid nitrogen and stored at −80°C. Coronal brain sections (20 μm) were obtained using a cryostat (CM1900, Leica) and mounted onto gelatin-coated glass slides for histological staining.
Penumbral tissue is operationally defined as the ischemic area that will undergo apoptosis without treatment but is rescued with treatment. The differences in infarct area between drug-treated MCAO groups and vehicle-treated MCAO group were considered as the penumbra as our previous studies described. 15 
Staining for Detecting Labile Zinc
Brain tissue sections were stained with the zinc-specific membranepermeable fluorescent dyes Newport Green (NG; N7990, Invitrogen, Eugene, OR) as previously described. 4 Sections were incubated with NG (10 μmol/L in PBS; pH, 7.4) for 3 minutes in the dark, then rinsed in saline.
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Evaluation of ROS Formation
ROS was detected using an oxidant-sensing fluorescent probe, 2′,7′-dichlorofluorescin diacetate (H 2 DCF-DA; Sigma-Aldrich). 10, 12 Brain sections were incubated in 10 µmol/L H 2 DCF-DA for 20 minutes, then rinsed in PBS. Superoxide generation was determined by fluorescent-labeled dihydroethidium (DHE; Sigma-Aldrich) staining. 17 Brain sections were stained with 100 μmol/L DHE in PBS for 90 minutes at room temperature.
For quantitative analysis of immunostaining, 5 brains for each experimental subgroup were measured. Every fourth section was selected (total=6 sections per brain). The number of NG-, H 2 DCF-DA-, or DHE-fluorescent cells in 3 fields (×200 magnification) randomly placed within penumbra tissue was counted under a fluorescence microscope (Nikon 80i) by a technician who was blinded to group assignment.
Costaining of Cytosolic Labile Zinc with ROS
Colocalization of zinc and ROS was performed to determine the relationship between Zn 2+ accumulation and ROS production. Slices were first incubated with DHE. After rinsing in PBS, the sections were incubated with NG. The nuclei were stained with 4′6-diamidino-2-phenylindole.
Costaining of Cytosolic ROS and Neuronal Cell Death
Colocalization of ROS and NeuN (neuron-specific nuclear protein) or terminal deoxynucleotidyl transferase-mediated dUTP nickend labeling was performed to determine the relationship between ROS production and neuronal cell death. Slices were first incubated with H 2 DCF-DA for 20 minutes. NeuN immunofluorescence staining with mouse anti-NeuN polyclonal antibody (1:100; Chemicon, Temecula, CA) as the primary antibody or terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining with In Situ Cell Death Detection Kit-POD (Roche, San Francisco, CA) was then performed. 4 
Statistical Analysis
Results are reported as mean±SD. The difference between means was assessed by the ANOVA and post hoc least significant difference/ Tamhane T2 tests for multiple comparisons, with P<0.05 considered statistically significant.
Results

Cytosolic Labile Zinc Accumulation Was Colocalized With ROS Production and Associated With Neuronal Cell Death in Ischemic Rats
To investigate the interaction between cytosolic labile zinc accumulation and ROS formation after cerebral ischemia, selective zinc-specific fluorescence indicator NG and ROS fluorescence indicator H 2 DCF-DA were used. There was none or few NG-fluorescent and H 2 DCF-DA-fluorescent cells in the sham group, whereas a drastic reperfusion timedependent increase of both NG-fluorescent cells and H 2 DCF-DA-fluorescent cells was observable in the penumbra tissue section at 6 and 24 hours after reperfusion ( Figure 1A and 1B), indicating that cytosolic labile zinc level and ROS formation kept on increasing after ischemia, at least up to 24 hours. Similar results were obtained by using another ROS fluorescent dye, DHE ( Figure 1C ). We also investigated the spatial relationship between zinc accumulation and ROS formation. NG-positive cells were found to colocalize with DHEpositive cells (Figure 1D ), indicating that cytosolic labile zinc accumulation and ROS production occurred in the same cells. These findings suggest that cytosolic labile zinc accumulation may be associated with ROS production in the ischemic brain.
We further investigated the cell-type specificity and outcome of the interaction between ROS formation and zinc accumulation. Figure 2A shows that H 2 DCF-DA-positive cells were largely colocalized with NeuN-positive cells, and Figure 2B shows that the majority of H 2 DCF-DA-stained cells displayed terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling positive. These results suggest that ischemia-induced ROS formation occurred in neurons, which may promote neuronal death after ischemia. Taken together, our findings indicate that focal ischemia induced a high level of zinc accumulation and ROS production in the neurons, resulting in neuronal death.
Chelating Zinc by TPEN Reduced ROS Formation and Brain Damage in Ischemic Rats
To examine the interaction between cytosolic labile zinc accumulation and ROS production, zinc chelator or ROS inhibitor were used. First, zinc chelator TPEN was used to remove cytosolic labile zinc in MCAO rats to probe whether zinc accumulation contributes to ROS production. The results indicate that chelating zinc with TPEN not only reduced the reperfusion time-dependent increase of NG-fluorescent cells in the penumbra of MCAO rat ( Figure 3A) , but more importantly, decreased the H 2 DCF-DA-fluorescent cells as well ( Figure 3B ). These findings demonstrate that zinc accumulation significantly contributed to ROS formation in ischemic brain.
Next, we investigated whether chelating zinc reduces ischemic brain damage. TPEN treatment significantly reduced MCAO-induced cerebral infarct at 6 and 24 hours after reperfusion ( Figure 3C ). This marked reduction in infarct volume could not be attributed to hypothermia or other alterations of physiological parameters because these parameters were essentially unchanged between sham and ischemic groups (Table I in the online-only Data Supplement). We also investigated neurological outcome of chelating zinc in ischemic rats using 3 independent methods. Treatment with TPEN significantly decreased neurological deficit scores, improved the behavioral deficits, and enhanced the functional recovery compared with vehicle-treated MCAO rats ( Figure 3D ). These results demonstrate that chelating zinc by TPEN reduces brain damage in ischemic rats.
Eliminating ROS by EUK-134 Decreased Brain
Damage in Ischemic Rats, but Only Reduced the Cytosolic Labile Zinc Accumulation at 24 Hours After Reperfusion SOD and catalase are important endogenous enzymes in scavenging ROS in ischemic brain. To investigate the effect of ROS production on cytosolic labile zinc accumulation, a synthetic ROS scavenger having both manganese-dependent superoxide dismutase and catalase activity, EUK-134, was used. Figure 4A shows that EUK-134 mostly eliminated the reperfusion time-dependent increase of H 2 DCF-DA-fluorescent cells in the penumbra tissue of MCAO rats. Interestingly, the 
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NG-fluorescent cells in the penumbra of EUK-134-treated MCAO rat did not change at 6 hours after reperfusion but decreased markedly at 24 hours after reperfusion ( Figure 4B ), suggesting that ROS had little effect on zinc accumulation at 6 hours after reperfusion but contributed significantly to zinc accumulation at 24 hours after reperfusion in ischemic rats. The MCAO-induced cerebral infarct was significantly reduced by EUK-134 treatment at both 6 and 24 hours after reperfusion ( Figure 4C ). EUK-134 treatment also significantly decreased neurological deficit scores, improved the behavioral deficits, and enhanced the functional recovery ( Figure 4D ). These results suggest that ROS was only involved in zinc accumulation at late phase of reperfusion and that scavenging ROS by EUK-134 reduces ischemic brain damage.
Suppression of Mitochondrial ROS Production by R(+)PPX Did Not Change Cytosolic Labile Zinc Accumulation, but Reduced Brain Damage in Ischemic Rats at 6 Hours After Reperfusion
To investigate the effect of ROS produced by mitochondria on cytosolic labile zinc accumulation, mitochondria-targeted ROS inhibitor R(+)PPX was used. As shown in Figure 5A , R(+)PPX reduced the H 2 DCF-DA-fluorescent cells significantly in the penumbra of MCAO rat at 6 hours, but not at 24 hours, after reperfusion, suggesting that ROS is mainly produced from mitochondria at 6 hours after reperfusion. At 24 hours after reperfusion, the majority of ROS in the penumbra of MCAO rat is produced from pathways other than mitochondria. The NG-fluorescent cells in the penumbra of R(+)PPX-treated MCAO rat did not change at 6 or 24 hours after reperfusion ( Figure 5B ), suggesting the mitochondrial ROS production had no effect on zinc accumulation in ischemic brain.
The MCAO-induced cerebral infarct was significantly reduced by R(+)PPX treatment at 6 hours after reperfusion ( Figure 5C ). Meanwhile, neurological deficit scores, behavioral deficits, and functional recovery of ischemic rats were also ameliorated ( Figure 5D) . Surprisingly, at 24 hours after reperfusion, the infarct volume and neurological deficits, as well as behavioral dysfunction in MCAO rats, were not affected by R(+)PPX treatment ( Figure 5C and 5D ). These unexpected findings indicate that the mitochondria-targeted antioxidants R(+)PPX reduced brain damage in ischemic rats only at 6 hours after reperfusion, consistent with the earlier finding ( Figure 5A ) that mitochondria-generated ROS occurs only at early phase (ie, 6 hours) but not at later phase of reperfusion (ie, 24 hours).
Suppression of NADPH Oxidase-Derived ROS Production Reduced Cytosolic Labile Zinc Accumulation and Brain Damage at 24 Hours After Reperfusion
To investigate the effect of ROS produced by NADPH oxidase on cytosolic labile zinc accumulation in cerebral ischemia, NADPH oxidase inhibitor DPI was used. As shown in Figure 6A , DPI only reduced the H 2 DCF-DA-fluorescent cells in the penumbra of MCAO rat at 24 hours, but not at 6 hours, after reperfusion, suggesting that ROS produced through NADPH oxidase pathway is mainly at 24 hours after reperfusion. At 6 hours after reperfusion, the ROS in the penumbra of MCAO rat is produced from pathways other than NADPH oxidase. Similarly, the NG-fluorescent cells in the penumbra of DPI-treated MCAO rat did not change at 6 hours after reperfusion but decreased significantly at 24 hours after reperfusion ( Figure 6B ), suggesting that the ROS produced by NADPH oxidase contributes to zinc accumulation at 24 hours after reperfusion in ischemic rats.
Compared with vehicle-treated MCAO rats, treatment with DPI significantly reduced MCAO-induced cerebral infarct, decreased neurological deficit scores, improved the behavioral deficits, and enhanced the functional recovery at 24 hours, but not at 6 hours, after reperfusion ( Figure 6C and 6D). The NADPH oxidase inhibitor DPI reduced ischemic brain damage only at 24 hours after reperfusion, supporting the idea that ROS produced through NADPH oxidase pathway was mainly at 24 hours after reperfusion. A and B; n=8 for C and D) . *P<0.05 vs vehicle-treated MCAO group.
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Discussion
The present study investigated the interaction between zinc and ROS after transient focal cerebral ischemia and explored the dynamic relationships of cytosolic labile zinc accumulation in relation to ROS-generating systems during the course of ischemia/reperfusion. We demonstrated that ischemia-triggered zinc release promoted mitochondrial ROS production, which was the major ROS source at early time after reperfusion (6 hours). Furthermore, mitochondrial ROS production had no influence on zinc accumulation, indicating the critical importance of spatial and temporal factors in the interaction between ROS and zinc accumulation. At 24 hours after reperfusion, activation of neuronal NADPH oxidase, which is the major ROS source at this time, led to further zinc accumulation, and zinc accumulation led to further ROS production, indicating that there exists a positive feedback loop between zinc accumulation and NADPH oxidase-induced ROS production in the ischemic brain, which contributes to subsequent neuronal death and brain injury. Although both zinc and ROS have been shown to contribute to brain injury after ischemia, the present study provides the first direct evidence that zinc increases ROS while ROS increases zinc, a zinc-ROS-zinc positive feedback loop to amplify the damaging effect of both, thus causing greater damage to the brain. Previous in vitro study showed that eliminating ROS by EUK-134 almost completely blocked all the consequences of Zn 2+ treatment. Zinc chelation prevents ROS production and neuronal death after hypoglycemia. 18 However, there is little in vivo evidence to prove whether labile cytosolic zinc accumulation is a cause or an effect of ROS production in ischemic brain injury. TPEN is a specific zinc chelator that is neuronal cell membrane permeable and that can bind and remove intracellular and extracellular labile zinc. Our previous studies demonstrate that 15 mg/kg TPEN treatment effectively reduced labile zinc generated in brain tissue after cerebral ischemia/reperfusion. 4 In this in vivo study, chelation of zinc by TPEN decreased ROS generation at both 6 and 24 hours after reperfusion. However, eliminating ROS by EUK-134 had no effect on zinc accumulation at 6 hours but reduced zinc accumulation at 24 hours after reperfusion, indicating that zinc promotes ROS production, while ROS production only contributes to zinc accumulation in neurons at later reperfusion time (24 hours). These results suggest that initial zinc release is the upstream of ROS production in the penumbra regions after cerebral ischemia/reperfusion.
It is reported that ROS production in hippocampal neurons during oxygen-glucose deprivation and chemical ischemia is primarily generated by the mitochondrial respiratory chain. 6 After focal ischemia, reperfusion was associated with partial recovery of mitochondrial respiratory function during the first hour then followed by deterioration between 2 and 4 hours, 19 suggesting that mitochondria probably is a major source of ROS production several hours after reperfusion. In this study, mitochondria-targeted neuroprotectant R(+)PPX reduced ROS formation and brain damage at 6 hours after reperfusion ( Figure 5A and 5C), while DPI, the inhibitor of NADPH oxidase, has little effect on ROS production at 6 hours after reperfusion ( Figure 6A ), suggesting that ROS produced at 6 hours after reperfusion is mainly from mitochondria.
Beside mitochondrial respiratory chain, recent studies aimed at determining the source of superoxide production in the neurons suggest that NADPH oxidase is a major source of superoxide production after hypoglycemia and in a cell culture model of ischemia/reperfusion. 5, 6, 20 We observed a small decrease of ROS production at 24 hours after reperfusion by mitochondria-targeted ROS inhibitor R(+)PPX (Figure 5A ), but the most profound inhibition was seen after inhibition of NADPH oxidase by DPI (Figure 6A) , suggesting that the majority of the ROS signal seen at 24 hours after reperfusion is generated by the NADPH oxidase.
Prior studies showed that oxidant-induced mobilization of endogenous Zn 2+ already in neurons could interfere with mitochondrial function. 8, 21 Zn 2+ accumulates rapidly in neurons and contributes to consequent mitochondrial dysfunction and cell death. 22 Our recent study showed that ischemia induced zinc accumulation in mitochondria. Treatment with TPEN stabilized the mitochondrial membrane potential and reduced cytochrome c release in the penumbra after cerebral ischemia, 15 supporting the idea that mitochondria may be the important targets of Zn 2+ in ischemia. The present study shows that chelating zinc reduced ROS formation and brain damage in ischemic rats at 6 hours after reperfusion ( Figure 3A through 3D) , indicating that zinc promotes mitochondrial ROS production after cerebral ischemia. However, suppression of mitochondrial ROS production did not change cytosolic labile zinc accumulation at 6 hours after reperfusion ( Figure 5B ), supporting the idea that zinc release is the upstream of mitochondrial ROS production after cerebral ischemia/reperfusion. At 24 hours after reperfusion, TPEN reduced ROS formation and ischemic brain damage. Meanwhile, DPI reduced cytosolic labile zinc accumulation and brain damage in ischemic rats, indicating that there exists a positive feedback between zinc accumulation and NADPH oxidase-induced ROS production, which contributes to subsequent neuronal death and brain injury after ischemia. Although it is well known that there are multiple sources contributing to ischemia-generated ROS, we demonstrate here that different sources contribute at different time, particularly in terms of interaction with zinc.
We previously reported that in cerebral ischemic rats, there was a dramatically elevated level of zinc accumulation in microvessels, showing the direct interaction of zinc on ischemic microvessels. Zinc accumulation in microvessels activated the superoxide/matrix metalloproteinase-9/-2 pathway, leading to the loss of tight junction proteins and death of endothelial cells in microvessels themselves. 23 NADPH oxidases are key enzymes in endothelial cells. Thus, although the current study was focused on neuronal injury, it is highly likely that the proposed pathways would be similar in endothelial cells as well.
Taken together, the present study delineates for the first time an ordered sequence and dynamic relationship between zinc and ROS that lead to neuronal death and brain injury after cerebral ischemia. Cerebral ischemia leads to zinc release, which in turn activates mitochondrial ROS production. Further zinc accumulation activates neuronal NADPH oxidase. ROS produced by NADPH oxidase leads to further increased zinc accumulation, resulting cell death
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and ischemic brain injury. These findings provide a novel mechanism explaining cerebral ischemia damage and implicate zinc-ROS-zinc as an effective and viable new target for treating ischemic stroke.
